New ADD Medicine

The Food and Drug Administration has given approval to Cephalon Inc. to market Sparlon as a treatment for attention-defict/hyperactivity disorder in children ages 6-17. Subject to FDA final approval, Sparlon is expected to be on the market by early next year. Final approval is contingent upon discussions between Cephalon and the FDA regarding the product's labeling.

Sparlon is a new formulation and dosage strength of modafinil, which is the active ingredient in Provigil. Provigil is Cephalon's product approved for the treatment of adults that struggle with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/ hypopnea syndrome and shift-work sleep disorder. It was going to originally be marketed under the name Attenace, but the FDA expressed concerns about the name prompting the change.